XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net loss $ (232,884,000) $ (241,375,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 2,649,000 2,618,000
Stock-based compensation expense 39,011,000 40,418,000
Write-off of prepaid manufacturing services related to the termination of CHS-2020 0 3,210,000
Write-downs of inventory 26,000,000 5,192,000
Non-cash interest expense from amortization of debt discount & issuance costs 5,631,000 3,150,000
Upfront and option payments to Junshi Biosciences 35,000,000 136,000,000
Loss on debt extinguishment 6,222,000  
Other non-cash adjustments, net 1,844,000 2,708,000
Changes in operating assets and liabilities:    
Trade receivables, net 31,849,000 20,722,000
Inventory (37,556,000) 2,936,000
Prepaid manufacturing (6,967,000) (2,884,000)
Other prepaid, current and non-current assets (12,509,000) (4,590,000)
Accounts payable (6,149,000) 30,495,000
Accrued rebates, fees and reserves (25,006,000) 3,215,000
Accrued compensation (623,000) (3,451,000)
Accrued and other current and non-current liabilities 32,317,000 16,526,000
Net cash (used in) provided by operating activities (141,171,000) 14,890,000
Investing activities    
Purchases of property and equipment (1,952,000) (821,000)
Purchases of investments in marketable securities   (171,779,000)
Proceeds from maturities of investments in marketable securities   62,700,000
Upfront and option payments to Junshi Biosciences (35,000,000) (136,000,000)
Net cash used in investing activities (36,952,000) (245,900,000)
Financing activities    
Proceeds from 2027 Term Loans, net of debt discount & issuance costs 240,679,000  
Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs   40,903,000
Proceeds from issuance of common stock upon exercise of stock options 631,000 9,726,000
Proceeds from purchase under the employee stock purchase plan 1,655,000 1,985,000
Taxes paid related to net share settlement of RSUs (3,621,000) (1,730,000)
Repayment of 2022 Convertible Notes and premiums (109,000,000)  
Repayment of 2025 Term Loan, premiums and exit fees (81,750,000)  
Other financing activities (861,000) (492,000)
Net cash provided by financing activities 47,733,000 50,392,000
Net decrease in cash, cash equivalents and restricted cash (130,390,000) (180,618,000)
Cash, cash equivalents and restricted cash at beginning of period 417,635,000 541,598,000
Cash, cash equivalents and restricted cash at end of period $ 287,245,000 $ 360,980,000